Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Alpelisib × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 Breast 1

Conditions

Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Breast Neoplasms 1

Interventions

selpercatinib 2 lutetium Lu 177 dotatate 2 entrectinib 2 cabozantinib 2 Fulvestrant 2 trametinib 1 ribociclib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 dabrafenib 1 copper dotatate CU-64 1 belzutifan 1 X-Rays 1 Specimen Handling 1 Phantoms, Imaging 1 Octreotide 1 Magnetic Resonance Spectroscopy 1 Lutetium-177 1 Lutetium 1 Alpelisib 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡